The inter- and intra-patient genetic heterogeneity of tumours means that different patients, with ostensibly the same tumour type, may respond differently to the same drug, and combinations of drugs may be needed in order to treat the multiple clones present within a tumour. We are developing molecular imaging methods to detect the early responses of tumours to treatment. These could be used in early stage clinical trials to get an early indication of drug efficacy and subsequently in the clinic to select the most effective drug, or drug combination, for individual patients. We have focused on methods for imaging tumour metabolism, which can give an early indication of whether a drug has engaged its target, and on methods for imaging the downstream consequences of this engagement, notably tumour cell death.​